IDYA as reported
IDEAYA Biosciences, Inc. reported $234M of revenue over the trailing twelve months. 8 reported series are charted on this page, each one as filed.
$234M
Revenue, trailing twelve months · to Q2 2026 · every figure below is as filed, with no scoring applied
- Net Income
- −$175M
Net Income · −47% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- −$114M
Free Cash Flow · −62% year on year · trailing twelve months to Q2 2026
- Op Margin
- −963%
Op Margin · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $234M | n/a | Q2 2026 |
| Net Income | −$175M | −47% | Q2 2026 |
| EPS | −$1.94 | −50% | Q2 2026 |
| Op Margin | −963% | n/a | Q2 2026 |
| Net Margin | −870% | n/a | Q2 2026 |
| ROE | −14% | n/a | Q2 2026 |
| ROA | −13% | n/a | Q2 2026 |
| Free Cash Flow | −$114M | −62% | Q2 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
IDEAYA Biosciences, Inc. (IDYA) - Revenue & ProfitRevenue & ProfitIDEAYA Biosciences, Inc. (IDYA)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com